Considering this is the era of personalized medicine, we need to raise the question of which candidates are suitable to benefit from exogenous GLP-1 RAs for not only glycemic control but also renal protection in T2DM patients. The gene discussed is GCG; the disease is type 2 diabetes mellitus.